<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS101540</article-id>
<article-id pub-id-type="doi">10.1101/2020.10.23.352294</article-id>
<article-id pub-id-type="archive">PPR230738</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>SARS-CoV-2 specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking and large-scale production for Adoptive Cell Therapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Ferreras</surname>
<given-names>C</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Pascual-Miguel</surname>
<given-names>B</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mestre-Durán</surname>
<given-names>C</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Navarro-Zapata</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Clares-Villa</surname>
<given-names>L</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martín-Cortázar</surname>
<given-names>C</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Paz</surname>
<given-names>R</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marcos</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vicario</surname>
<given-names>JL</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Balas</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>García-Sánchez</surname>
<given-names>F</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eguizabal</surname>
<given-names>C</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Solano</surname>
<given-names>C</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mora-Rillo</surname>
<given-names>M</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soria</surname>
<given-names>B</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pérez-Martínez</surname>
<given-names>B</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A10">10</xref>
<xref ref-type="aff" rid="A11">11</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Hospital La Paz Institute for Health Research, IdiPAZ, La Paz University Hospital, Madrid, Spain</aff>
<aff id="A2">
<label>2</label>University Hospital La Paz, Hematology Department, Madrid, Spain</aff>
<aff id="A3">
<label>3</label>Histocompatibility. Centro de Transfusión de Madrid. Madrid, Spain</aff>
<aff id="A4">
<label>4</label>Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Bizkaia, Spain</aff>
<aff id="A5">
<label>5</label>Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain</aff>
<aff id="A6">
<label>6</label>Hospital Clínico Universitario de Valencia/Instituto de Investigación Sanitaria INCLIVA, Universidad de Valencia</aff>
<aff id="A7">
<label>7</label>Infectious Diseases Unit, Internal Medicine Department, University Hospital La Paz, - Hospital La Paz Institute for Health Research, IdiPAZ, La Paz University Hospital, Madrid, Spain</aff>
<aff id="A8">
<label>8</label>Instituto de Bioingeniería, Universidad Miguel Hernández de Elche, Alicant</aff>
<aff id="A9">
<label>9</label>Instituto de Investigación Sanitaria Hospital General y Universitario de Alicante ISABIAL</aff>
<aff id="A10">
<label>10</label>University Hospital La Paz, Pediatric Hemato-oncology Department, Madrid, Spain</aff>
<aff id="A11">
<label>11</label>Faculty of Medicine Universidad Autónoma de Madrid, Madrid, Spain</aff>
<author-notes>
<corresp id="CR1">Corresponding author: Antonio Pérez-Martínez MD, PhD; Servicio de Hemato-Oncología Pediátrica, Hospital Infantil Universitario La Paz, Paseo de la Castellana 261, Madrid, 28046, Spain. Phone: +34917277223; fax: +34917277042. <email>aperezmartinez@salud.madrid.org</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>28</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>26</day>
<month>10</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
<license license-type="open-access" xlink:href="https://europepmc.org/downloads/openaccess">
<license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">SARS-CoV-2 is causing a second outbreak so the hope for its complete eradication is far from happening. In the absence of effective vaccines, it is mandatory to find effective treatments with low adverse effects able to treat hospitalized patients with COVID-19 disease. In this work, we determined the existence of SARS-CoV-2 specific T cells within the CD45RA<sup>-</sup> T memory cells from the blood of convalescent donors. Memory T cells can respond quickly to the infection and provide long-term immune protection to reduce the severity of the COVID-19 symptoms. Also, CD45RA<sup>-</sup> memory T cells confer protection from other pathogens the donors encountered in their life. This is vital to clear other secondary infections usually developed in hospitalized COVID-19 patients. SARS-CoV-2 specific memory T cells were found within all the CD45RAsubsets CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, and in the central memory and effector memory subpopulations. The procedure to obtain the cells is feasible, easy to implement for small scale manufacture, quick and cost-effective involving minimal manipulation, and without GMP condition requirements. This biobank of specific SARS-CoV-2 memory T cells would be immediately available ‘off-the-shelf’ to treat moderate/severe cases of COVID-19 increasing the therapeutic options available for these patients.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">The new severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 has emerged causing a worldwide pandemic from late 2019. This coronavirus is causing an infectious disease called COVID-19 with a wide range and diverse symptoms. In most infected patients the illness generates mild symptoms including fever and cough but, in some others, causes a life-threatening disease with symptoms that include pneumonia, dyspnea and a hyperinflammatory process which includes cytokine storm, systemic immunethrombosis, etc. Patients suffering from these symptoms need hospitalization and treatment. A common feature of this severe disease is lymphopenia making them more vulnerable to co-infections and correlating with the severity of the disease<sup>
<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>
</sup>. With strong restrictive measures, social distancing, and healthcare interventions the first wave was contained, although thousands of patients died. Far from disappearing SARS-CoV- 2 is causing a second wave thus diminishing the hope of its complete eradication. Vaccine development actively pursues to generate active immunity through vaccine immunization<sup>
<xref ref-type="bibr" rid="R3">3</xref>
</sup> but there is uncertainty about how long antibody-mediated immune response to COVID-19 will last<sup>
<xref ref-type="bibr" rid="R4">4</xref>
</sup>. We need effective treatments that can reduce the severity of symptoms, time of hospitalization and increase survival.</p>
<p id="P3">So far, the only treatment for COVID-19 is supportive. Antiviral treatment with lopinavir—ritonavir is not effective in improving outcomes for hospitalized patients with COVID-19<sup>
<xref ref-type="bibr" rid="R5">5</xref>
</sup>; also, remdesivir has been recently approved to treat COVID-19 although its beneficial effect is still controversial<sup>
<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R7">7</xref>
</sup>. Preliminary results with anti-inflammatory therapies such as dexamethasone<sup>
<xref ref-type="bibr" rid="R8">8</xref>
</sup> or mesenchymal stromal cells<sup>
<xref ref-type="bibr" rid="R9">9</xref>
</sup> have shown promising results for critical patients (WHO Grade 6 and 7)<sup>
<xref ref-type="bibr" rid="R10">10</xref>
</sup>, but we do not have yet an effective antiviral therapy able to stop the progress of this diseases at early stages: (WHO Grade 1-4 moderate and severe) or even to prevent COVID-19.</p>
<p id="P4">The role of the adaptive immunity in COVID-19 disease and the protective immunity conferred by T cells is being characterized<sup>
<xref ref-type="bibr" rid="R11">11</xref>
</sup>–<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup> but the role of memory T cells conferring protection against SARS-CoV-2 has not been properly defined yet. The existence of memory T cells specific for another SARS coronavirus was found up to 11 years postinfection<sup>
<xref ref-type="bibr" rid="R16">16</xref>
</sup>. This immunological memory creates a more rapid and robust secondary immune response to reinfections. This fact is determinant and constitutes the basis of adoptive cell therapy of viral infections in immunosuppressed patients in the context of allogeneic hematopoietic stem cell transplantation (HSCT). In HSCT the infusion of CD45RA<sup>-</sup> memory T cells has considerably reduced the morbidity and mortality induced by viral reactivations such as cytomegalovirus (CMV) or Epstein Barr Virus (EBV) and, at the same time, has reduced the alloreactivity conferred by the naïve CD45RA<sup>+</sup> T cells<sup>
<xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R21">21</xref>
</sup>.</p>
<p id="P5">Memory T cells do appear when T lymphocytes recognize a pathogen presented by their local antigen-presenting cells. These T cells activate, proliferate, and differentiate into effector cells secreting molecules to control the infection. Once the pathogen has been cleared most of the antigen-specific T cells disappear and a pool of heterogeneous longlived memory T cells persist<sup>
<xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref>
</sup>. This population of memory T cells defined as CD45RA<sup>-</sup> or CD45RO<sup>+</sup> is maintained over time conferring a quick and long-term immune protection against subsequent reinfections<sup>
<xref ref-type="bibr" rid="R24">24</xref>
</sup>,<sup>
<xref ref-type="bibr" rid="R25">25</xref>
</sup>.</p>
<p id="P6">In this work, we report the existence of a SARS-CoV-2 specific T cell population within the CD45RA- T memory cells from the blood of convalescent donors that can be easily, effectively, and rapidly isolated by CD45RA depletion. These specific SARS-CoV-2 CD45RA- T memory cells may be able to clear virally infected cells and to confer T cell immunity for subsequent reinfections. These cells can be stored to be used in moderate and severe cases of hospitalized COVID-19 patients becoming an off-the-self living drug.</p>
</sec>
<sec id="S2" sec-type="methods">
<title>Methods</title>
<sec id="S3">
<title>Donors’ characteristics</title>
<p id="P7">
<xref ref-type="table" rid="T1">Table 1</xref> shows the donors’ characteristics. Six COVID-19 convalescent donors and two healthy controls were included. The convalescent donors were all tested for SARSCoV- 2 by reverse-transcriptase polymerase chain reaction (RT-PCR) in nasopharyngeal samples between March and April 2020. Eligibility criteria included age 21 to 65, a history of COVID-19 with documented positive RT-PCR test for SARS-CoV-2. At the time of this study, they were all tested negative for SARS-CoV-2. The median age of the convalescent donors was 37 years old (range 23-41), three were females and three were males. The median days until PCR negative for SARS-CoV-2 was 13 days (range 5-17). Two of them presented with bilateral pneumonia but no hospitalization was needed. Just one of them received treatment with oral hydroxycloroquine + azytromicine + lopinariv/ritonavir and another one was treated with oral hydroxycloroquine + azytromicine. Two healthy donors were enrolled who have not been exposed to COVID-19 patients and were tested negative for anti-SARS-CoV-2 antibodies in June 2020. All the participants gave written consent with approval by the Hospital Institution Review Board (IRB number: 254/20)</p>
</sec>
<sec id="S4">
<title>Cell processing and detection of SASR-CoV-2 specific memory T cells by IFN-γ assay</title>
<p id="P8">Peripheral Blood Mononuclear Cells (PBMCs) from healthy donors and the convalescent donors were isolated from their peripheral blood by density gradient centrifugation using Ficoll-Paque (GE Healthcare, Illinois, Chicago, USA). Briefly, cells were rested overnight (o/n) at 37ºC in TexMACS Medium (Miltenyi Biotec, Bergisch Gladbach, Germany) supplemented with 10% AB serum (Sigma-Aldrich, Saint Louis, Missouri, USA) and 1% Penicillin/Streptomycin (Sigma-Aldrich, Saint Louis, Missouri, USA). The next day 1x10<sup>6</sup> cells were stimulated with pooled or individual overlapping SARS-CoV-2 peptides at a final concentration of 0.6 nmol/ml. For positive control, 1x10<sup>6</sup> cells were stimulated in the presence of plate-bound stimulator OKT3 at a final concentration of 2.8 μg/ml (mouse anti-human CD3 Clone OKT3 BD Biosciences). Cells with SARS-CoV-2 peptides and positive control were co-stimulated with CD28/CD49d at a final concentration of 5 μg/ml (anti-human CD28/CD49d Purified Clone L293 L25 BD Biosciences). Basal IFN-γ production by PBMCs was included as background control in the absence of stimulation and costimulation. The peptide pools were short 15-mer peptides with 11 amino acid overlaps which can bind MHC class I and class II complexes and thus were able to stimulate both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. The peptides cover the immunodominant sequence domains of the surface glycoprotein S, and the complete sequence of the nucleocapsid phosphoprotein N and the membrane glycoprotein M (GenBank MN908947.3, Protein QHD43416.1, Protein QHD43423.2, Protein QHD43419.1) (Miltenyi Biotec, Germany). After 5 hours of stimulation, the cells were labeled with the IFN-γ Catch Reagent (IFN-γSecretion Assay-Detection Kit, human Miltenyi Biotec) containing bispecific antibodies for CD45 and γ which was secreted by the stimulated target cells. After the secretion phase, the cell surface-bound γ was targeted using the IFN-γ PE antibody included in the kit.</p>
</sec>
<sec id="S5">
<title>Phenotype of memory T cells containing SARS-CoV-2 specific T cells by flow cytometry assay</title>
<p id="P9">Analysis of the cell composition in the T cells specifically activated by SARS-Cov-2 in the γ assay was performed by subtracting the basal cytokine response from the background control. Cell surface staining was performed for 20 minutes at 4 degrees with the following fluorochrome-conjugated antibodies titrated to their optimal concentrations:, CD45RA FITC (BD Pharmingen), CD27 APC (BD Pharmingen), CD3 viogreen (Miltenyi Biotec), CD4 PECy7 (BD Pharmingen), CD8 APC Cy7 (BD Pharmingen), 7AAD (BD Horizon). For the Treg panel CD25 BV421 (BD Horizon), and CD127 PE-CF594 (BD Horizon), were used. For the activation panel HLA-DR BV 421 (BD Pharmingen), CD69 BV421 (Biolegend), CD25 BV421 (BD Horizon), were used. For the exhaustion panel PD1 AF700 (Biolegend), NKG2A BV421 (Biolegend) were used. For the chemokine panel, CD103 BV421 (BD Horizon) and CCR7 PECF594 (BD Horizon) were used. An average of 200.000 cells was acquired. Cell acquisition was performed using a Navios cytometer (Beckman Coulter). The analysis was performed using FlowJo 10.7.1 (FlowJo LLC).</p>
</sec>
<sec id="S6">
<title>IL15 stimulation of memory T cells</title>
<p id="P10">CD45RA<sup>-</sup> memory T lymphocytes from the convalescent donor were thawed and stimulated with IL15 to obtain an activated phenotype. Cells were incubated in TexMACS Medium (Miltenyi Biotec, Germany) supplemented with 5% AB serum (Sigma-Aldrich, Saint Louis, Missouri, USA) and 1% Penicillin/Streptomycin (Sigma- Aldrich, Saint Louis, Missouri, USA) plus 50 ng/ml of IL15 o/n and for 72 hours. After that time the cells were harvested and the phenotypic assay was performed. The same culture without IL15 was run in parallel as a control.</p>
</sec>
<sec id="S7">
<title>Donor selection, HLA typing, and large clinical scale CD45RA<sup>+</sup> T cell depletion</title>
<p id="P11">Criteria for the convalescent donor selection were: secretion of γ upon activation with the 3 SARS-CoV-2 specific peptides (M, N, S) and the most frequent HLA typing to cover most of the population. The HLA phenotype of the convalescent donor was done at the Centro de Transfusión of the Comunidad of Madrid on two independent samples by SSO and NGS: A*02:01,A*24:02 / B*44:02,B*51:01 / C*16:02,C*16:04 / DRB1*07:01,DRB1*11:03 / DQB1*02:02,DQB1*03:01.</p>
<p id="P12">Non-mobilized apheresis was performed at the Bone Marrow Transplant and Cell Therapy Unit for University Hospital La Paz, Madrid, Spain by using CliniMACS Plus device (Milteny Biotec). The donor gave written informed consent by the Declaration of Helsinki protocol, and the study was performed according to the guidelines of the local ethics committee (IRB Number 5579). The donor complied with the requirements regarding quality and safety for the donation, obtaining, storage, distribution, and preservation of human cells and tissues under the Spanish specific regulation. Following apheresis, CD45RA<sup>+</sup> cells were depleted by immunomagnetic separation using a CliniMACS CD45RA Reagent and CliniMACS Plus system, both from Miltenyi Biotec, following manufacturer instructions. CD45RA<sup>-</sup> cells were frozen using autologous plasma plus 5% dimethyl sulfoxide (DMSO) and stored. We were able to cryopreserve 30 aliquots at different doses according to the trial design. The viability, purity, phenotype and spectratyping of CD45RA- fraction were analyzed by flow cytometry (FCM).</p>
</sec>
<sec id="S8">
<title>TCR spectratyping</title>
<p id="P13">Most of the CDR3-encoding regions of the TCRV-β and -γ genes were amplified using 2 V-J multi-primer sets for each locus and one additional multi-primer set covering D-J TCRV-? (Vitro, Master Diagnostica, Spain). Primers marked at their 5’ end with 6- FAM fluorochrome, allowed denatured fragment size analysis by capillary electrophoresis (ABI3130 DNA-analyzer) and Genemapper software (Thermo Fisher Scientific, USA).</p>
</sec>
<sec id="S9">
<title>Statistical analysis</title>
<p id="P14">Quantitative variables are expressed as Mean + Standard Deviation (SD). Qualitative variables are expressed in percentages (%). Two-tailed Mann-Whitney non-parametric test was used for comparison means for non-paired samples using GraphPad Prism (version 8.0.0 for Windows, GraphPad Software, San Diego, California USA). A P value &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="S10" sec-type="results">
<title>Results</title>
<sec id="S11">
<title>Memory T cells from convalescent donors contain a SARS-CoV-2 specific population</title>
<p id="P15">PBMCs of the convalescent and healthy donors were stimulated with the three overlapping peptides (M, N, S) specific of SARS-CoV-2 for 5 hours. We detected the existence of SARS-CoV-2 specific population by the production of IFN-γ in both subsets naïve CD45RA+ and memory CD45RA- T cells in the PBMCs of the convalescent donors but not in healthy controls (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F1">Figure 1</xref>). They also showed reactivity for the single peptides M, N, and S (data not shown). The mean CD45RA-CD3+ population in the convalescent donors was close to 90%. Expression of IFN-γ within CD45RA-CD3+ population was 1.12% whereas the expression of IFN-γ within CD45RA+CD3+ population was 0.40% (P=0.065) (<xref ref-type="table" rid="T2">Table 2</xref>). We didn’t detect the expression of γ in healthy individuals. Despite is a small cohort we didn’t find a synergistic effect on the percentage of IFN-γ when the three peptides are mixed when compared to the single peptides (data not shown).</p>
</sec>
<sec id="S12">
<title>Identification of SARS-CoV-2 specific CD4<sup>+</sup> T and CD8<sup>+</sup> T cell responses within CD45RA- memory T cells</title>
<p id="P16">Then, we asked whether both CD8+ and CD4+ subsets contained specific SARS-CoV-2 T cells within the PBMCs of the convalescent donors. Among all subsets studied we observed that CD45RA-CD4+ and CD45RA-CD8+ cells expressed 1.25% and 0.85% of IFN-γ respectively (P= 0.132). (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F2">Figure 2</xref>, and data not shown). Thus, all the convalescent donors recovered from COVID-19 generated CD4+ T and CD8+ T cells responses against SARS-CoV-2 within the memory CD45RA- T cell population.</p>
<p id="P17">We then analysed the T central memory (CM) (CD45RA-CD3+CD27+) and T effector memory (EM) (CD45RA-CD3+CD27-) compartments. While no significant differences were detected, we observed responses to the SARS-CoV-2 specific peptides within all subpopulations. Within the CD4+ and CD8+ CM T cell subsets we detected a mean of 1.26% and 0.79% of IFN-γ<sup>+</sup>cells respectively (P=0.132). Looking at the CD4+ and CD8+ EM T cell subsets we detected a mean of 1.25% and 1.06% of IFN-γ<sup>+</sup> cells respectively (P=0.108). (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F3">Figure 3</xref>). These data show the existence of a population of memory T cells specific for SARS-CoV-2 within the CD45RA-CD3+ memory T cells.</p>
</sec>
<sec id="S13">
<title>Large-scale CD45RA depletion. Creation of an off-the self-biobank of CD45RAmemory T cells from a COVID-19 convalescent donor</title>
<p id="P18">Blood donor apheresis was performed followed by CD45RA<sup>+</sup> T cell depletion as described in Material and Methods. After depletion of CD45RA+ cells, 99.8% of the cells were CD45RA-CD3+. Cells were cryopreserved and stored. Most of the CD45RO+ cells were CD4+ with a high CD4/CD8 ratio. The viability after thawing was 98-99%.</p>
</sec>
<sec id="S14">
<title>Identification of SARS-CoV-2 specific CD4<sup>+</sup> T and CD8<sup>+</sup> T cell responses within CD45RA<sup>-</sup> memory T cells after CD45RA depletion</title>
<p id="P19">After CD45RA depletion, the percentage of CD45RA<sup>-</sup>CD3<sup>+</sup> cells was 80.05%. Within that population 83.56% of the cells were CD4<sup>+</sup> and 14.37% were CD8<sup>+</sup> T cells. After exposure to the three peptides specific for SARS-CoV-2, we found that CD3<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> subsets expressed γ with percentages of 0.36, 0.38, and 0.31 respectively. (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<p id="P20">Within the EM and CM compartments, most of the CD4<sup>+</sup> and CD8<sup>+</sup> cells had a CM phenotype (89.1% v 61.6%). Both subpopulations CM and EM expressed IFN-γ after exposure with the three peptides. Within CD4<sup>+</sup> CM, CD8<sup>+</sup> CM and CD4<sup>+</sup> EM subsets we found that 0.38%, 0.70% and 0.39% of cells respectively expressed IFN-γ. We didn’t find a specific expression of γ within the CD8<sup>+</sup> EM subset. (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<p id="P21">Then, we characterized in-depth the phenotypic expression of activation, exhaustion, and Treg markers within the CD45RA<sup>-</sup> population of the convalescent donor. The number of Treg defined by CD127<sup>low</sup>CD25<sup>+</sup> was 11.26%. We found that the CD45RACD3<sup>+</sup> expressed the activation marker HLA-DR (19.40%) in both subsets of cells CD4<sup>+</sup> (16.70%) and CD8<sup>+</sup> (29.19%). After exposure to the three SARS-CoV-2 specific peptides we found that within CD3<sup>+</sup>HLA<sup>-</sup>DR<sup>+</sup>, CD4<sup>+</sup>HLA<sup>-</sup>DR<sup>+</sup>, and CD8<sup>+</sup>HLA-DR<sup>+</sup> populations 0.93%, 0.70% and 1.21% of the cells respectively were IFN-γ<sup>+</sup>. Also, the CD45RA<sup>-</sup>CD3<sup>+</sup> expressed the exhaustion marker NKG2A (1.88%) and this expression was 10.24% within the CD8+ subset whereas it was nearly undetectable in CD4<sup>+</sup> cells (0.14%). We didn’t find expression of IFN-γ within the NKG2A<sup>+</sup> population. Also, 0.70% of the CD45RA-CD3+ cells expressed the exhaustion marker PD-1, this expression was 1.43% within the CD4+ subset and 0.13% within the CD8+ cells. We found 0.62% of IFN-γ+ cells within the CD45RA-CD3+CD4+PD-1+ population after exposure to the three peptides. (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
</sec>
<sec id="S15">
<title>CDR3 use of TCR</title>
<p id="P22">Polyclonal distribution for both TCR-β and -γ CDR3-encoding regions was almost identical among control and CD45RA-, whereas different oligoclonal fragments were seen in the CD45RA+ population. Three of the oligoclonal fragments seen in CD45RA+ cells were also identified in CD45RA- (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p>
</sec>
<sec id="S16">
<title>Induction of an activated memory T cells phenotype within CD45RA<sup>-</sup> memory T cells after CD45RA depletion</title>
<p id="P23">IL15 is a cytokine fundamental for memory T cells that induces the activation, proliferation, and survival of T cells. To induce an activated phenotype of memory T cells we incubated the CD45RA- T cells with IL15 o/n and for 72 hours (<xref ref-type="table" rid="T3">Table 3</xref>). We observed a fold increase of the activation markers HLA-DR, CD69, and CD25 after 72 h of incubation (2.63, 29.59, 8.52) when compared to o/n incubation (1.15, 3.18, 1.50). The expression of the exhaustion markers NKG2A and PD-1 were also higher after 72 hours of incubation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figures 1</xref>-<xref ref-type="supplementary-material" rid="SD5">5</xref>). Then, we looked at the expression of chemokine CCR7 and the integrin CD103 important for homing to the air tract respiratory<sup>
<xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R27">27</xref>
</sup>. We observed that most of the CD3<sup>+</sup>CD4<sup>+</sup> cells expressed CCR7<sup>+</sup> cells (88.13%) and the CD3<sup>+</sup>CD8<sup>+</sup> subpopulation expressed 45.42% of CCR7<sup>+</sup> cells. The expression of CD103 was low in peripheral blood as expected26. We detected that the expression in the CD3<sup>+</sup>CD103<sup>+</sup>, CD3<sup>+</sup>CD8<sup>+</sup>CD103<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup>CD103<sup>+</sup> compartments was 2.18%, 5.96% and 1.38% respectively. Although the fold increase was not very remarkable in the CD45RA<sup>-</sup>CD3<sup>+</sup> cells after 72 hours of incubation (1.00- fold CCR7 and 1.24-fold CD103), the increase was higher (1.40) within the CD8<sup>+</sup> subpopulation (<xref ref-type="table" rid="T3">Table 3</xref> and <xref ref-type="supplementary-material" rid="SD6">Supplementary Figures 6</xref>, <xref ref-type="supplementary-material" rid="SD7">7</xref>).</p>
</sec>
</sec>
<sec id="S17" sec-type="discussion">
<title>Discussion</title>
<p id="P24">In the absence of an effective vaccine, and with the emergence of a second wave there is an urgent need to find effective treatments for COVID-19 disease. Here we report the existence of a SARS-CoV-2 specific T cell population within the CD45RA<sup>-</sup> T memory cells of the blood from the convalescent donors. These cells can be easily, effectively, and rapidly isolated following a donor selection strategy based on the expression of γ after exposure with SARS-CoV-2 specific peptides and HLA antigen expression. This way we can obtain clinical-grade CD45RA<sup>-</sup> memory T lymphocytes from the blood of convalescent donors, biobanking, thawing, and using them as a treatment for moderate/severe cases of COVID-19. These so-called “living drugs” retain memory against SARS-CoV-2 and other pathogens they have encountered previously. Unlike plasma where the concentration decreases after infusion, memory T cells expand and proliferate, so we hypothesize that will have a more lasting effect.</p>
<p id="P25">In previous studies this population of CD45RA<sup>-</sup> memory T cells have shown no alloreactivity when compared to the CD45RA<sup>+</sup> counterpart<sup>
<xref ref-type="bibr" rid="R28">28</xref>
</sup>, they are mainly CD4<sup>+</sup>
<sup>
<xref ref-type="bibr" rid="R29">29</xref>
</sup> and they have shown to be effective against viral infections<sup>
<xref ref-type="bibr" rid="R20">20</xref>
</sup>. Phenotypically we found that CD45RA<sup>-</sup> memory T cells were fully capable of producing IFN-γ in the presence of SARS-CoV-2 specific peptides. Both CD4<sup>+</sup> and CD8<sup>+</sup> CM and EM subsets were able to generate γ? after exposure to the SARS-CoV-2 peptides showing coverage of response. CD8<sup>+</sup> cytotoxic cells can kill virally infected cells by secreting cytokines, at the same time CD4<sup>+</sup> T cells increase the ability of the CD8<sup>+</sup> T cells in eliminating the virus. They have been shown to play an important role in controlling the viral replication of other viruses such as EBV and CMV<sup>
<xref ref-type="bibr" rid="R30">30</xref>
</sup>. EM are the first responders to the infection with a quick and strong response to pathogens whereas CM proliferate and create a new round of effector T cells<sup>
<xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R31">31</xref>
</sup>. IL15 is essential for the survival of memory CD8<sup>+</sup> and CD4<sup>+</sup> T cells subsets promoting the activation of CD4+T cells including cytokine production, proliferation, and maintenance of memory population<sup>
<xref ref-type="bibr" rid="R32">32</xref>
</sup>,<sup>
<xref ref-type="bibr" rid="R33">33</xref>
</sup>. After incubating for 3 days with IL15 we obtained phenotype characteristic of an activated state as is shown by the fold increase in the activation markers HLA-DR, CD69, and CD25 and in CCR7 and CD103 markers characteristic of homing to the lymph nodes and mucosal tissues.</p>
<p id="P26">In our study, we did not observe the production of γ by SARS-Cov-2 specific T cells in healthy unexposed individuals which is in agreement with the data from Peng Y et al<sup>
<xref ref-type="bibr" rid="R34">34</xref>
</sup> but differs from previously published data<sup>
<xref ref-type="bibr" rid="R14">14</xref>
</sup>. This could also due to the different detection methods used and the small sample size.</p>
<p id="P27">Studies have shown that the correlation between neutralizing antibodies and the severity of the symptoms where antibody responses wane over time even in a short period as 6-7 weeks after the onset of symptoms<sup>
<xref ref-type="bibr" rid="R35">35</xref>–<xref ref-type="bibr" rid="R37">37</xref>
</sup>. Importantly our data shows the existence of the SARS-CoV-2 memory T cells in convalescent donors with mild symptoms. This has a great implication for the protection from the next SARS-CoV-2 infections and to decrease the severity of COVID-19 disease. Further studies with a larger cohort to determine the duration of memory to SARS-CoV-2 will be needed to elucidate longterm protection to SARS-CoV-2 as it has been shown for another coronavirus previously<sup>
<xref ref-type="bibr" rid="R16">16</xref>
</sup>.</p>
<p id="P28">For the proper T cell recognition, both donor and recipient need to share HLA alleles. Given the vast number of convalescent donors to find a right haploidentical donor based on HLA typing would not be difficult. We estimate that based on HLA donor-recipient match four donors will cover almost the whole country population<sup>
<xref ref-type="bibr" rid="R38">38</xref>
</sup>.</p>
<p id="P29">The procedure to obtain the cells is easy to implement for small scale manufacture, quick and cost-effective involving minimal manipulation and without GMP condition requirements. These factors make feasible the generation of a biobank or stock from the blood of convalescent donors that would be immediately available ‘off the shelf’ for subsequent outbreaks of the pandemic increasing the therapeutic options available in the current SARS-CoV-2 pandemic. The safety of these cells in moderate/severe patients with COVID-19 is currently assessed in a clinical trial (NCT04578210).</p>
<p id="P30">These cells could provide to the patient: 1) a pool of SARS-CoV-2 specific T cells that will respond quickly to the infection, 2) a pool of lymphocytes to patients with severe disease presenting with lymphopenia and 3) a pool of specific memory T cells for other pathogens from the donors encountered in their life which are vital to clear other secondary infections usually developed in hospitalized patient COVID-19<sup>
<xref ref-type="bibr" rid="R39">39</xref>,<xref ref-type="bibr" rid="R40">40</xref>
</sup>.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplemental Figure 1</label>
<media xlink:href="EMS101540-supplement-Supplemental_Figure_1.TIF" mimetype="image" mime-subtype="tiff" id="N66616" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<label>Supplemental Figure 2</label>
<media xlink:href="EMS101540-supplement-Supplemental_Figure_2.TIF" mimetype="image" mime-subtype="tiff" id="N66625" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD3">
<label>Supplemental Figure 3</label>
<media xlink:href="EMS101540-supplement-Supplemental_Figure_3.TIF" mimetype="image" mime-subtype="tiff" id="N66634" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD4">
<label>Supplemental Figure 4</label>
<media xlink:href="EMS101540-supplement-Supplemental_Figure_4.TIF" mimetype="image" mime-subtype="tiff" id="N66643" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD5">
<label>Supplemental Figure 5</label>
<media xlink:href="EMS101540-supplement-Supplemental_Figure_5.TIF" mimetype="image" mime-subtype="tiff" id="N66652" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD6">
<label>Supplemental Figure 6</label>
<media xlink:href="EMS101540-supplement-Supplemental_Figure_6.TIF" mimetype="image" mime-subtype="tiff" id="N66661" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD7">
<label>Supplemental Figure 7</label>
<media xlink:href="EMS101540-supplement-Supplemental_Figure_7.TIF" mimetype="image" mime-subtype="tiff" id="N66670" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S18">
<title>Acknowledgments</title>
<p>We thank the donors for their blood donation and the CRIS Cancer Foundation (<ext-link ext-link-type="uri" xlink:href="http://criscancer.org">http://criscancer.org</ext-link>) and the Generalitat Valenciana AVI-GVA COVID-19-68 for their support.</p>
</ack>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P31">
<bold>Contributors</bold>
</p>
<p id="P32">CF, BS, and A P-M designed the study. CF, BP-M and CM-D performed the in vitro experiments. JLV, AB, FGS performed HLA typing and TCR spectratyping. R D-Paz and AM performed the non-mobilized apheresis and cryopreservation of the cells. CM performed the statistics. CF, BP-M, BS and A P-M wrote the first draft of the manuscript. All authors revised the manuscript, participated in the interpretation of the data, approval of the manuscript, and submission.</p>
</fn>
<fn id="FN2" fn-type="conflict">
<p id="P33">
<bold>Conflict of interest</bold>
</p>
<p id="P34">CF, BS and AP-M filed a patent on this topic.</p>
<p id="P35">BS received fees from Celgene, Gilead, Sanofi and Novo-Nordisk not related to this work.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China</article-title>
<source>Clin Infect Dis</source>
<year>2020</year>
<month>Jul</month>
<day>28</day>
<volume>71</volume>
<issue>15</issue>
<fpage>762</fpage>
<lpage>768</lpage>
<pub-id pub-id-type="doi">10.1093/cid/ciaa248</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systematic review and meta-analysis</article-title>
<source>Int J Infect Dis</source>
<year>2020</year>
<month>Jul</month>
<volume>96</volume>
<fpage>131</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijid.2020.04.086</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thanh Le</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Andreadakis</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gómez Román</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tollefsen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Saville</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>The COVID-19 vaccine development landscape</article-title>
<source>Nat Rev Drug Discov</source>
<year>2020</year>
<volume>19</volume>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>T cell responses to whole SARS coronavirus in humans</article-title>
<source>Journal of Immunology</source>
<year>2008</year>
<volume>181</volume>
<issue>8</issue>
<fpage>5490</fpage>
<lpage>5500</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.181.8.5490</pub-id>
<comment>Baltimore, Md. 1950</comment>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hayden</surname>
<given-names>FG</given-names>
</name>
</person-group>
<article-title>Antiviral monotherapy for hospitalised patients with COVID-19 is not enough</article-title>
<source>The Lancet</source>
<year>2020</year>
<month>October</month>
<day>5</day>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)32078-X</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</article-title>
<source>The Lancet</source>
<year>2020</year>
<month>May</month>
<day>16</day>
<volume>395</volume>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31022-9</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jomah</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Asdaq</surname>
<given-names>SMB</given-names>
</name>
<name>
<surname>Al-Yamani</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<source>Clinical efficacy of antivirals against novel coronavirus (COVID-19) Journal of infection and Public Health 13</source>
<year>2020</year>
<fpage>1187</fpage>
<lpage>1195</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<collab>RECOVERY Collaborative Group</collab>
<article-title>Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<month>Jul</month>
<day>17</day>
<volume>71</volume>
<comment>NEJMoa2021436 Epub ahead of print</comment>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez Guijo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>García-Arranz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Parra-López</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Monedero</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mata- Martínez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study</article-title>
<source>EclinicalMedicine</source>
<year>2020</year>
<volume>25</volume>
<comment>100454</comment>
<pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100454</pub-id>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="web">
<label>10</label>
<collab>World Health Organization</collab>
<source>World Health Organization and R&amp;D Blueprint strategy for COVID-19</source>
<date-in-citation>Accessed Oct 12, 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/teams/blueprint/covid-19">https://www.who.int/teams/blueprint/covid-19</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Garcia-Carreras</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hitchings</surname>
<given-names>MDT</given-names>
</name>
</person-group>
<source>medRxiv preprint</source>
<pub-id pub-id-type="doi">10.1101/2020.04.14.20065771</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wing</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Soh</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Linn</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>JGH</given-names>
</name>
<name>
<surname>Loh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Rapid production of clinical-grade SARS-CoV-2 specific T cells</article-title>
<source>Adv Cell Gene Ther</source>
<year>2020</year>
<volume>00</volume>
<pub-id pub-id-type="doi">10.1002/acg2.101</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekine</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pérez-Potti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rivera-Ballesteros</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Stralin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gorin</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Robust T Cell Immunity in Convalescent individuals with Asymptomatic or Mild COVID-19</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>158</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2020.08.017</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weiskopf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Mateus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Moderbacher</surname>
<given-names>CR</given-names>
</name>
<etal/>
</person-group>
<article-title>Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<issue>7</issue>
<fpage>1489</fpage>
<lpage>1501</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodda</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Netland</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shehata</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pruner</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Morawski</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Thouvenel</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Functional SASR-CoV-2- specific immune memory persists after mild COVID-19</article-title>
<source>medRxiv preprint</source>
<pub-id pub-id-type="doi">10.1101/2020.08.11.20171843.th</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ng</surname>
<given-names>OW</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Jadi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Leong</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Bertoletti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>YJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Memory T cell responses targeting the SARS coronavirus persist up to 11 years postinfection</article-title>
<source>Vaccine</source>
<year>2016</year>
<month>Apr</month>
<day>12</day>
<volume>34</volume>
<issue>17</issue>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.063</pub-id>
<fpage>2008</fpage>
<lpage>2014</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bleakley</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heimfeld</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Turtle</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Riddell</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Shlomchik</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Engineering Human Peripheral Blood Stem Cell Grafts that are Depleted of NaÏve T cells and retain Functional Pathogen- Specific Memory T cells</article-title>
<source>Biol Blood Marrow Transplant</source>
<year>2014</year>
<fpage>705</fpage>
<lpage>716</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbmt.2014.01.032</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teschner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Distler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wehler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marandiuc</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Langeveld</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis</article-title>
<source>Bone Marrow Transplant</source>
<year>2014</year>
<month>Jan</month>
<volume>49</volume>
<issue>1</issue>
<fpage>138</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1038/bmt.2013.114</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bleakley</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heimfield</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Loeb</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Chaney</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Seropian</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Outcomes of acute leukemia patients transplanted with naÏve T cell-depleted stem cell grafts</article-title>
<source>J Clin Invest</source>
<year>2015</year>
<volume>125</volume>
<issue>7</issue>
<fpage>2677</fpage>
<lpage>2689</lpage>
<pub-id pub-id-type="doi">10.1172/jci81229</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Triplett</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shook</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Eldridge</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dallas</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies</article-title>
<source>Bone Marrow Transplant</source>
<year>2015</year>
<month>Jul</month>
<volume>50</volume>
<issue>7</issue>
<fpage>968</fpage>
<lpage>977</lpage>
<pub-id pub-id-type="doi">10.1038/bmt.2014.324</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Triplett</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Moen</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared to CD3-targeted T-cell depletion</article-title>
<source>Transpl Infect Dis</source>
<year>2018</year>
<month>February</month>
<volume>20</volume>
<issue>1</issue>
<pub-id pub-id-type="doi">10.1111/tid.12823</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pennock</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>White</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Cheney</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Tamburini</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Kedl</surname>
<given-names>RM</given-names>
</name>
<etal/>
</person-group>
<article-title>T cell responses: naÏve to memory and everything in between</article-title>
<source>Adv Physiol Educ</source>
<year>2013</year>
<volume>37</volume>
<issue>15</issue>
<fpage>273</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1152/advan.00066.2013</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Gebhardt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Carbone</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>WR</given-names>
</name>
</person-group>
<article-title>Memory T cell subsets, migration patterns, and tissue residence</article-title>
<source>Annu Rev Immunol</source>
<year>2013</year>
<volume>31</volume>
<fpage>137</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095954</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Channappanavar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>T cell-mediated immune response to respiratory coronaviruses</article-title>
<source>Immunol Res</source>
<year>2014</year>
<volume>59</volume>
<fpage>118</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1007/s12026-014-8534-z</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tough</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Qualitative differences between naÏve and memory T cells</article-title>
<source>Inmunology</source>
<year>2002</year>
<volume>106</volume>
<fpage>127</fpage>
<lpage>138</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-2567.2002.01447.x</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uss</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rowshani</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Hooibrink</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lardy</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>van Lier</surname>
<given-names>RAW</given-names>
</name>
<name>
<surname>ten Berge</surname>
<given-names>IJM</given-names>
</name>
<etal/>
</person-group>
<article-title>CD103 Is a Marker for Alloantigen-Induced Regulatory CD8+ T Cells</article-title>
<source>J Immunol</source>
<year>2006</year>
<volume>177</volume>
<fpage>2775</fpage>
<lpage>2783</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.177.5.2775</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Kunkel</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Brightling</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Soler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>CCR7 expression and Memory T cell diversity in humans</article-title>
<source>J Immunol</source>
<year>2001</year>
<volume>166</volume>
<fpage>877</fpage>
<lpage>884</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.166.2.877</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernández</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Metais</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Escudero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vela</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Valentín</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vallcorba</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>
<article-title>Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells</article-title>
<source>Clin Cancer Res</source>
<year>2017</year>
<month>Oct</month>
<day>1</day>
<volume>23</volume>
<issue>19</issue>
<fpage>5824</fpage>
<lpage>5835</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0075</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernández</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fernández</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mirones</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Escudero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vela</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy</article-title>
<source>Front Immunol</source>
<year>2019</year>
<volume>10</volume>
<fpage>2361</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2019.02361</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juno</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>van Bocker</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kent</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kelleher</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Zaunders</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Munier</surname>
<given-names>CML</given-names>
</name>
<etal/>
</person-group>
<article-title>Cytotoxic CD4 T Cells—Friend or Foe during Viral Infection?</article-title>
<source>Front Immunol</source>
<year>2017</year>
<volume>8</volume>
<fpage>19</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2017.00019</pub-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farber</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Yudanin</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Restifo</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Human memory T cells: generation, compartmentalization and homeostasis</article-title>
<source>Nat Rev Immunol</source>
<year>2014</year>
<month>January</month>
<volume>14</volume>
<issue>1</issue>
<fpage>24</fpage>
<lpage>35</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brincks</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Woodland</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>Novel roles for IL15 in T cell survival F1000</article-title>
<source>Biol Rep</source>
<year>2010</year>
<volume>2</volume>
<fpage>67</fpage>
<pub-id pub-id-type="doi">10.3410/B2-6</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>XL</given-names>
</name>
<name>
<surname>Bobbala</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Donates</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Mayhue</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ilangumaran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ramanathan</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>IL15 trans-presentation regulates homeostasis of CD4+</article-title>
<source>Cell Mol Immunol</source>
<year>2014</year>
<month>Jul</month>
<volume>11</volume>
<issue>4</issue>
<fpage>387</fpage>
<lpage>397</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mentzer</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad and strong memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19</article-title>
<source>Nat Immunol</source>
<year>2020</year>
<volume>21</volume>
<fpage>1336</fpage>
<lpage>1345</lpage>
<pub-id pub-id-type="doi">10.1038/s41590-020-0782-6</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seow</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Merrick</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Acors</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Steel</surname>
<given-names>KJA</given-names>
</name>
<name>
<surname>Hemmings</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>
<source>Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection</source>
<pub-id pub-id-type="doi">10.1101/2020.07.09.20148429</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibarrondo</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Fulcher</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Goodman-Meza</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Elliot</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hofmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hausner</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>
<article-title>Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<month>September</month>
<day>10</day>
<volume>383</volume>
<fpage>11</fpage>
<lpage>768</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMc2025179</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>QX</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>XJ</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>QL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</article-title>
<source>Nat Med</source>
<year>2020</year>
<volume>26</volume>
<fpage>1200</fpage>
<lpage>1204</lpage>
<pub-id pub-id-type="doi">10.1038/s41591-020-0965-6</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Bollard</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Mendizabal</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Shpall</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Szabolcs</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Antin</surname>
<given-names>JH</given-names>
</name>
<etal/>
</person-group>
<article-title>Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation</article-title>
<source>Blood</source>
<year>2013</year>
<month>Jun</month>
<day>27</day>
<volume>121</volume>
<issue>26</issue>
<fpage>5113</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2013-02-486324</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Co-infection with respiratory pathogens among COVID-2019 cases</article-title>
<source>Virus Research</source>
<year>2020</year>
<volume>285</volume>
<comment>198005</comment>
<pub-id pub-id-type="doi">10.1016/j.virusres.2020.198005</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pinsky</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>
<article-title>Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens</article-title>
<source>JAMA</source>
<year>2020</year>
<month>May</month>
<day>26</day>
<volume>323</volume>
<issue>20</issue>
<fpage>2085</fpage>
<lpage>2086</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2020.6266</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Representative figure of the expression of IFN-γ in a convalescent and healthy donor within the CD45RA<sup>+</sup> and CD45RA<sup>-</sup> subpopulations after co-culture with the mixture of the three peptides (M, N, S)</p>
</caption>
<graphic xlink:href="EMS101540-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Representative figure of the expression of IFN-γ in a convalescent donor within the CD45RA<sup>-</sup>CD3<sup>+</sup>CD4<sup>+</sup> and CD45RA<sup>-</sup>CD3<sup>+</sup>CD8<sup>+</sup> subpopulations after coculture with the mixture of the three peptides (M, N, S)</p>
</caption>
<graphic xlink:href="EMS101540-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Representative figure of the gating strategy of the different cells subsets within the CD45RA<sup>-</sup> population and the IFN-γ expressed. CM= central memory, EM=effector memory</p>
</caption>
<graphic xlink:href="EMS101540-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>TCR-β and -γ spectratyping for 5 multi-primer sets covering most of the CDR3-encoding regions. Electropherograms showing gaussian distribution of polyclonal population (Control) is also mainly seen in CD45RA<sup>-</sup>, with oligoclonal patterns in CD45RA<sup>+</sup>. Some predominant fragments are shared in both convalescent donor populations.</p>
</caption>
<graphic xlink:href="EMS101540-f004"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Participants’ characteristics</title>
</caption>
<table frame="box" rules="all">
<tbody>
<tr>
<td align="left" valign="top">Number of donors</td>
<td align="center" valign="top">6</td>
</tr>
<tr>
<td align="left" valign="top">Mean age (range)</td>
<td align="center" valign="top">37 (23-41)</td>
</tr>
<tr>
<td align="left" valign="top">Gender (female/male)</td>
<td align="center" valign="top">3/3</td>
</tr>
<tr>
<td align="left" valign="top">Days to SARS-CoV-2 negative PCR (range)</td>
<td align="center" valign="top">12.83 (5-17)</td>
</tr>
<tr>
<td align="left" valign="top">Bilateral pneumonia, n(%)</td>
<td align="center" valign="top">2 (33.3%)</td>
</tr>
<tr>
<td align="left" valign="top">Days until samples taken from negative PCR (range)</td>
<td align="center" valign="top">14.70 (7-33)</td>
</tr>
<tr>
<td align="left" valign="top">Ambulatory, n (%)</td>
<td align="center" valign="top">6 (100%)</td>
</tr>
<tr>
<td align="left" valign="top">
<bold>Treatment</bold>
</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Acetaminophen</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top">Hydroxycloroquine+azytromicine+ lopinariv/ritonavir</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">Hydroxycloroquine+azytromicine</td>
<td align="center" valign="top">1</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float" orientation="portrait">
<label>Table 2</label>
<caption>
<title>Immunophenotypic characterization of the healthy controls and the convalescent donors after co-culture with the mixture of the three SARS-CoV-2 peptides (M, N, S)</title>
</caption>
<table frame="box" rules="all">
<tbody>
<tr>
<th align="left" valign="top">Cell type</th>
<th align="left" valign="top">Subpopulations</th>
<th align="center" valign="top">C1</th>
<th align="center" valign="top">C2</th>
<th align="center" valign="top">Mean Pepx3</th>
<th align="center" valign="top">SD</th>
<th align="center" valign="top">D1</th>
<th align="center" valign="top">D2</th>
<th align="center" valign="top">D3</th>
<th align="center" valign="top">D4</th>
<th align="center" valign="top">D5</th>
<th align="center" valign="top">D6</th>
<th align="center" valign="top">Mean Pepx3</th>
<th align="center" valign="top">SD</th>
</tr>
<tr>
<td align="left" valign="top">CD45RA-</td>
<td align="left" valign="top">% CD45RA-</td>
<td align="center" valign="top">37.68</td>
<td align="center" valign="top">22.17</td>
<td align="center" valign="top">29.93</td>
<td align="center" valign="top">10.97</td>
<td align="center" valign="top">31.20</td>
<td align="center" valign="top">24.07</td>
<td align="center" valign="top">18.16</td>
<td align="center" valign="top">43.90</td>
<td align="center" valign="top">19.90</td>
<td align="center" valign="top">33.24</td>
<td align="center" valign="top">28.41</td>
<td align="center" valign="top">9.67</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.77</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.99</td>
<td align="center" valign="top" style="background-color:#d9d9d9">3.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.30</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.90</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.87</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.14</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.94</td>
</tr>
<tr>
<td align="left" valign="top">CD45RA-CD3+</td>
<td align="left" valign="top">% CD3+</td>
<td align="center" valign="top">61.69</td>
<td align="center" valign="top">78.38</td>
<td align="center" valign="top">70.04</td>
<td align="center" valign="top">11.80</td>
<td align="center" valign="top">93.84</td>
<td align="center" valign="top">93.45</td>
<td align="center" valign="top">94.53</td>
<td align="center" valign="top">77.12</td>
<td align="center" valign="top">86.64</td>
<td align="center" valign="top">94.48</td>
<td align="center" valign="top">90.01</td>
<td align="center" valign="top">6.99</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.69</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.79</td>
<td align="center" valign="top" style="background-color:#d9d9d9">3.03</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.34</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.01</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.83</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.12</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.96</td>
</tr>
<tr>
<td align="left" valign="top">CD45RA-CD8+</td>
<td align="left" valign="top">% CD8+</td>
<td align="center" valign="top">17.14</td>
<td align="center" valign="top">9.97</td>
<td align="center" valign="top">13.56</td>
<td align="center" valign="top">5.07</td>
<td align="center" valign="top">17.02</td>
<td align="center" valign="top">22.17</td>
<td align="center" valign="top">16.27</td>
<td align="center" valign="top">26.62</td>
<td align="center" valign="top">11.88</td>
<td align="center" valign="top">35.07</td>
<td align="center" valign="top">21.51</td>
<td align="center" valign="top">8.37</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.38</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.46</td>
<td align="center" valign="top" style="background-color:#d9d9d9">3.45</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.12</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.70</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.85</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.29</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">% CD8+ CM</td>
<td align="center" valign="top">87.86</td>
<td align="center" valign="top">87.29</td>
<td align="center" valign="top">87.58</td>
<td align="center" valign="top">0.40</td>
<td align="center" valign="top">86.52</td>
<td align="center" valign="top">65.72</td>
<td align="center" valign="top">76.30</td>
<td align="center" valign="top">88.00</td>
<td align="center" valign="top">90.01</td>
<td align="center" valign="top">42.50</td>
<td align="center" valign="top">74.84</td>
<td align="center" valign="top">18.28</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.31</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.33</td>
<td align="center" valign="top" style="background-color:#d9d9d9">2.88</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.11</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.64</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.48</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.79</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.04</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">% CD8+ EM</td>
<td align="center" valign="top">12.06</td>
<td align="center" valign="top">12.67</td>
<td align="center" valign="top">12.37</td>
<td align="center" valign="top">0.43</td>
<td align="center" valign="top">13.44</td>
<td align="center" valign="top">34.25</td>
<td align="center" valign="top">23.70</td>
<td align="center" valign="top">11.94</td>
<td align="center" valign="top">9.85</td>
<td align="center" valign="top">57.47</td>
<td align="center" valign="top">25.11</td>
<td align="center" valign="top">18.30</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.79</td>
<td align="center" valign="top" style="background-color:#d9d9d9">5.58</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.06</td>
<td align="center" valign="top" style="background-color:#d9d9d9">2.23</td>
</tr>
<tr>
<td align="left" valign="top">CD45RA-CD4+</td>
<td align="left" valign="top">% CD4+</td>
<td align="center" valign="top">68.15</td>
<td align="center" valign="top">86.69</td>
<td align="center" valign="top">77.42</td>
<td align="center" valign="top">13.11</td>
<td align="center" valign="top">75.99</td>
<td align="center" valign="top">75.83</td>
<td align="center" valign="top">79.31</td>
<td align="center" valign="top">70.60</td>
<td align="center" valign="top">80.07</td>
<td align="center" valign="top">60.63</td>
<td align="center" valign="top">73.74</td>
<td align="center" valign="top">7.24</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.81</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.91</td>
<td align="center" valign="top" style="background-color:#d9d9d9">2.93</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.43</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.11</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.32</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.25</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.87</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">% CD4+ CM</td>
<td align="center" valign="top">89.09</td>
<td align="center" valign="top">81.50</td>
<td align="center" valign="top">85.30</td>
<td align="center" valign="top">5.37</td>
<td align="center" valign="top">70.76</td>
<td align="center" valign="top">86.05</td>
<td align="center" valign="top">90.34</td>
<td align="center" valign="top">82.88</td>
<td align="center" valign="top">91.94</td>
<td align="center" valign="top">90.78</td>
<td align="center" valign="top">85.46</td>
<td align="center" valign="top">7.96</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.56</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.01</td>
<td align="center" valign="top" style="background-color:#d9d9d9">2.93</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.47</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.13</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.44</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.26</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.89</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">% CD4+ EM</td>
<td align="center" valign="top">10.87</td>
<td align="center" valign="top">18.47</td>
<td align="center" valign="top">14.67</td>
<td align="center" valign="top">5.37</td>
<td align="center" valign="top">29.23</td>
<td align="center" valign="top">13.94</td>
<td align="center" valign="top">9.66</td>
<td align="center" valign="top">17.10</td>
<td align="center" valign="top">8.01</td>
<td align="center" valign="top">9.22</td>
<td align="center" valign="top">14.53</td>
<td align="center" valign="top">7.97</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.37</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.39</td>
<td align="center" valign="top" style="background-color:#d9d9d9">3.17</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.21</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.35</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.98</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.25</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.06</td>
</tr>
<tr>
<td align="left" valign="top">
<bold>CD45RA+</bold>
</td>
<td align="left" valign="top">CD45RA+</td>
<td align="center" valign="top">61.91</td>
<td align="center" valign="top">77.83</td>
<td align="center" valign="top">69.87</td>
<td align="center" valign="top">11.26</td>
<td align="center" valign="top">68.69</td>
<td align="center" valign="top">75.86</td>
<td align="center" valign="top">81.86</td>
<td align="center" valign="top">55.98</td>
<td align="center" valign="top">80.30</td>
<td align="center" valign="top">66.75</td>
<td align="center" valign="top">71.57</td>
<td align="center" valign="top">9.74</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.02</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.01</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.67</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.93</td>
<td align="center" valign="top" style="background-color:#d9d9d9">6.47</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.10</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.52</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.32</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.50</td>
<td align="center" valign="top" style="background-color:#d9d9d9">2.45</td>
</tr>
<tr>
<td align="left" valign="top">CD45RA+CD3+</td>
<td align="left" valign="top">% CD3+</td>
<td align="center" valign="top">70.44</td>
<td align="center" valign="top">78.05</td>
<td align="center" valign="top">74.25</td>
<td align="center" valign="top">5.38</td>
<td align="center" valign="top">52.93</td>
<td align="center" valign="top">79.05</td>
<td align="center" valign="top">60.97</td>
<td align="center" valign="top">59.8</td>
<td align="center" valign="top">74.60</td>
<td align="center" valign="top">79.16</td>
<td align="center" valign="top">67.75</td>
<td align="center" valign="top">11.26</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.02</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.01</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.02</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.40</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.27</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.25</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.06</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.23</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.17</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.40</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.43</td>
</tr>
<tr>
<td align="left" valign="top">CD45RA+CD8+</td>
<td align="left" valign="top">% CD8+</td>
<td align="center" valign="top">22.77</td>
<td align="center" valign="top">24.35</td>
<td align="center" valign="top">23.56</td>
<td align="center" valign="top">1.12</td>
<td align="center" valign="top">56.52</td>
<td align="center" valign="top">27.24</td>
<td align="center" valign="top">49.85</td>
<td align="center" valign="top">32.1</td>
<td align="center" valign="top">33.08</td>
<td align="center" valign="top">38.60</td>
<td align="center" valign="top">39.57</td>
<td align="center" valign="top">11.34</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.13</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.46</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.69</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.09</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.41</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.21</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.50</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.60</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">% CD8+ Naive</td>
<td align="center" valign="top">72.84</td>
<td align="center" valign="top">83.57</td>
<td align="center" valign="top">78.21</td>
<td align="center" valign="top">7.59</td>
<td align="center" valign="top">76.57</td>
<td align="center" valign="top">84.64</td>
<td align="center" valign="top">80.40</td>
<td align="center" valign="top">95.9</td>
<td align="center" valign="top">80.80</td>
<td align="center" valign="top">44.83</td>
<td align="center" valign="top">77.19</td>
<td align="center" valign="top">17.19</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.17</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.22</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.51</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.10</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.29</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.15</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.24</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.15</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">% CD8+ TEMRA</td>
<td align="center" valign="top">27.14</td>
<td align="center" valign="top">16.43</td>
<td align="center" valign="top">21.79</td>
<td align="center" valign="top">7.57</td>
<td align="center" valign="top">23.43</td>
<td align="center" valign="top">15.35</td>
<td align="center" valign="top">19.60</td>
<td align="center" valign="top">4.1</td>
<td align="center" valign="top">19.20</td>
<td align="center" valign="top">55.17</td>
<td align="center" valign="top">22.81</td>
<td align="center" valign="top">17.19</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.07</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.81</td>
<td align="center" valign="top" style="background-color:#d9d9d9">7.02</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1,37</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0,29</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.76</td>
<td align="center" valign="top" style="background-color:#d9d9d9">2.68</td>
</tr>
<tr>
<td align="left" valign="top">CD45RA+ CD4+</td>
<td align="left" valign="top">% CD4+</td>
<td align="center" valign="top">70.26</td>
<td align="center" valign="top">70.09</td>
<td align="center" valign="top">70.18</td>
<td align="center" valign="top">0.12</td>
<td align="center" valign="top">32.35</td>
<td align="center" valign="top">70.30</td>
<td align="center" valign="top">47.27</td>
<td align="center" valign="top">65.88</td>
<td align="center" valign="top">59,50</td>
<td align="center" valign="top">54,40</td>
<td align="center" valign="top">54.95</td>
<td align="center" valign="top">13.75</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.47</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.14</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.55</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.06</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.22</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.09</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.26</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.21</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">% CD4+ Naive</td>
<td align="center" valign="top">99.53</td>
<td align="center" valign="top">98.72</td>
<td align="center" valign="top">99.13</td>
<td align="center" valign="top">0.57</td>
<td align="center" valign="top">95.67</td>
<td align="center" valign="top">99.53</td>
<td align="center" valign="top">99.32</td>
<td align="center" valign="top">99.57</td>
<td align="center" valign="top">99.35</td>
<td align="center" valign="top">99.21</td>
<td align="center" valign="top">98.78</td>
<td align="center" valign="top">1.53</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.21</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.13</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.52</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.07</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.21</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.09</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.21</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.16</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">% CD4+ TEMRA</td>
<td align="center" valign="top">0.47</td>
<td align="center" valign="top">1.28</td>
<td align="center" valign="top">0.88</td>
<td align="center" valign="top">0.57</td>
<td align="center" valign="top">4.33</td>
<td align="center" valign="top">0.47</td>
<td align="center" valign="top">0.68</td>
<td align="center" valign="top">0.43</td>
<td align="center" valign="top">0.65</td>
<td align="center" valign="top">0.79</td>
<td align="center" valign="top">1.23</td>
<td align="center" valign="top">1.53</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#d9d9d9"/>
<td align="left" valign="top" style="background-color:#d9d9d9">IFNγ+</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">5.77</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">2.30</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">0.00</td>
<td align="center" valign="top" style="background-color:#d9d9d9">1.35</td>
<td align="center" valign="top" style="background-color:#d9d9d9">2.35</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<p id="P36">The media value after 5 hours exposure of the three SARS-Cov-2 peptides (M,N,S) is shown. SD: Standard deviation; C= healthy controls; D= convalescent donors; Pepx3= mixture of the single SARS-Cov-2 peptides M,N,S</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" position="float" orientation="portrait">
<label>Table 3</label>
<caption>
<title>Phenotype of CD45RA memory T cells from a convalescent donor after large scale CD45RA depletion</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="top"/>
<th align="center" valign="top" style="background-color:#d9d9d9">Cell marker</th>
<th align="center" valign="top" style="background-color:#d9d9d9">% of cells after thawing</th>
<th align="center" valign="top" style="background-color:#d9d9d9">% IFNγ<sup>+</sup>
</th>
<th align="center" valign="top" style="background-color:#d9d9d9">Fold change IL15 (o/n)<xref ref-type="table-fn" rid="TFN2">*</xref>
</th>
<th align="center" valign="top" style="background-color:#d9d9d9">Fold change IL15 (72h)<xref ref-type="table-fn" rid="TFN3">**</xref>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="top" rowspan="11" style="background-color:#d9d9d9">
<bold>CD45RA-subpopulations</bold>
</td>
<td align="left" valign="top">
<bold>CD45RA<sup>-</sup>
</bold>
</td>
<td align="center" valign="top">99.85</td>
<td align="center" valign="top">0.36</td>
<td align="center" valign="top">1.00</td>
<td align="center" valign="top">0.99</td>
</tr>
<tr>
<td align="left" valign="top">CD45RA<sup>-</sup>CD3<sup>+</sup>
</td>
<td align="center" valign="top">80.05</td>
<td align="center" valign="top">0.36</td>
<td align="center" valign="top">1.05</td>
<td align="center" valign="top">0.99</td>
</tr>
<tr>
<td align="left" valign="top">CD45RA<sup>-</sup>CD3<sup>+</sup>CD4<sup>+</sup>
</td>
<td align="center" valign="top">83.56</td>
<td align="center" valign="top">0.38</td>
<td align="center" valign="top">1.02</td>
<td align="center" valign="top">0.98</td>
</tr>
<tr>
<td align="left" valign="top">CD45RA<sup>-</sup>CD3<sup>+</sup>CD8<sup>+</sup>
</td>
<td align="center" valign="top">14.37</td>
<td align="center" valign="top">0.31</td>
<td align="center" valign="top">0.84</td>
<td align="center" valign="top">1.10</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5" style="background-color:#d9d9d9">
<bold>CD45RA<sup>-</sup> CD4<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">CD27<sup>+</sup> (CM)</td>
<td align="center" valign="top">89.13</td>
<td align="center" valign="top">0.38</td>
<td align="center" valign="top">1.01</td>
<td align="center" valign="top">1.02</td>
</tr>
<tr>
<td align="left" valign="top">CD27<sup>-</sup>(EM)</td>
<td align="center" valign="top">10.86</td>
<td align="center" valign="top">0.39</td>
<td align="center" valign="top">0.94</td>
<td align="center" valign="top">0.86</td>
</tr>
<tr>
<td align="left" valign="top">CD127lowCD25<sup>+</sup> (Treg)</td>
<td align="center" valign="top">11.26</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">1.27</td>
<td align="center" valign="top">2.03</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5" style="background-color:#d9d9d9">
<bold>CD45RA<sup>-</sup> CD8<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">CD27<sup>+</sup> (CM)</td>
<td align="center" valign="top">61.65</td>
<td align="center" valign="top">0.70</td>
<td align="center" valign="top">1.07</td>
<td align="center" valign="top">1.03</td>
</tr>
<tr>
<td align="left" valign="top">CD27<sup>-</sup>(EM)</td>
<td align="center" valign="top">38.34</td>
<td align="center" valign="top">0.00</td>
<td align="center" valign="top">0.89</td>
<td align="center" valign="top">0.95</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="12" style="background-color:#d9d9d9">
<bold>T cell activation marker</bold>
</td>
<td align="left" valign="top" colspan="5">
<bold>CD3<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">HLA<sup>-</sup>DR<sup>+</sup>
</td>
<td align="center" valign="top">19.40</td>
<td align="center" valign="top">0.93</td>
<td align="center" valign="top">1.15</td>
<td align="center" valign="top">2.63</td>
</tr>
<tr>
<td align="left" valign="top">CD69 BV421 high</td>
<td align="center" valign="top">0.46</td>
<td align="center" valign="top">0.00</td>
<td align="center" valign="top">3.18</td>
<td align="center" valign="top">29.59</td>
</tr>
<tr>
<td align="left" valign="top">CD25<sup>+</sup>
</td>
<td align="center" valign="top">60.68</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">1.50</td>
<td align="center" valign="top">8.52</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5" style="background-color:#d9d9d9">
<bold>CD4<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">HLA-DR<sup>+</sup>
</td>
<td align="center" valign="top">16.70</td>
<td align="center" valign="top">0.70</td>
<td align="center" valign="top">1.16</td>
<td align="center" valign="top">2.42</td>
</tr>
<tr>
<td align="left" valign="top">CD69 BV421 high</td>
<td align="center" valign="top">0.38</td>
<td align="center" valign="top">0.00</td>
<td align="center" valign="top">2.90</td>
<td align="center" valign="top">59.75</td>
</tr>
<tr>
<td align="left" valign="top">CD25<sup>+</sup>
</td>
<td align="center" valign="top">66.10</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">1.48</td>
<td align="center" valign="top">8.58</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5" style="background-color:#d9d9d9">
<bold>CD8<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">HLA-DR<sup>+</sup>
</td>
<td align="center" valign="top">29.19</td>
<td align="center" valign="top">1.21</td>
<td align="center" valign="top">1.15</td>
<td align="center" valign="top">1.89</td>
</tr>
<tr>
<td align="left" valign="top">CD69 BV421 high</td>
<td align="center" valign="top">0.31</td>
<td align="center" valign="top">1.04</td>
<td align="center" valign="top">2.77</td>
<td align="center" valign="top">5.64</td>
</tr>
<tr>
<td align="left" valign="top">CD25<sup>+</sup>
</td>
<td align="center" valign="top">9.60</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">4.42</td>
<td align="center" valign="top">36.42</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="10" style="background-color:#d9d9d9">
<bold>T cell Exhaustion markers</bold>
</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5" style="background-color:#d9d9d9">
<bold>CD3<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">NKG2A<sup>+</sup>
</td>
<td align="center" valign="top">1.88</td>
<td align="center" valign="top">0.00</td>
<td align="center" valign="top">0.73</td>
<td align="center" valign="top">1.39</td>
</tr>
<tr>
<td align="left" valign="top">PD1 AF700</td>
<td align="center" valign="top">0.70</td>
<td align="center" valign="top">0.75</td>
<td align="center" valign="top">0.71</td>
<td align="center" valign="top">8.70</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5" style="background-color:#d9d9d9">
<bold>CD4<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">NKG2A<sup>+</sup>
</td>
<td align="center" valign="top">0.14</td>
<td align="center" valign="top">0.00</td>
<td align="center" valign="top">1.24</td>
<td align="center" valign="top">0.56</td>
</tr>
<tr>
<td align="left" valign="top">PD1 AF700</td>
<td align="center" valign="top">1.43</td>
<td align="center" valign="top">0.62</td>
<td align="center" valign="top">0.84</td>
<td align="center" valign="top">9.15</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5">
<bold>CD8<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">NKG2A<sup>+</sup>
</td>
<td align="center" valign="top">10.24</td>
<td align="center" valign="top">0.00</td>
<td align="center" valign="top">0.76</td>
<td align="center" valign="top">1.22</td>
</tr>
<tr>
<td align="left" valign="top">PD1 AF700</td>
<td align="center" valign="top">0.13</td>
<td align="center" valign="top">0.00</td>
<td align="center" valign="top">1.69</td>
<td align="center" valign="top">6.14</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="10" style="background-color:#d9d9d9">
<bold>Chemokine receptor and integrin</bold>
</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5" style="background-color:#d9d9d9">
<bold>CD3<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">CCR7</td>
<td align="center" valign="top">81.00</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">1.03</td>
<td align="center" valign="top">1.00</td>
</tr>
<tr>
<td align="left" valign="top">CD103</td>
<td align="center" valign="top">2.18</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">0.74</td>
<td align="center" valign="top">1.24</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5" style="background-color:#d9d9d9">
<bold>CD4<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">CCR7</td>
<td align="center" valign="top">88.13</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">1.00</td>
<td align="center" valign="top">0.97</td>
</tr>
<tr>
<td align="left" valign="top">CD103</td>
<td align="center" valign="top">1.38</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">0.74</td>
<td align="center" valign="top">0.99</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5" style="background-color:#d9d9d9">
<bold>CD8<sup>+</sup>
</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">CCR7</td>
<td align="center" valign="top">45.42</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">1.48</td>
<td align="center" valign="top">1.40</td>
</tr>
<tr>
<td align="left" valign="top">CD103</td>
<td align="center" valign="top">5.96</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">0.89</td>
<td align="center" valign="top">1.39</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN2">
<label>*</label>
<p id="P37">Fold change increase after the treatment with IL15 overnight (o/n).</p>
</fn>
<fn id="TFN3">
<label>**</label>
<p id="P38">Fold change increase after 72 hours with IL15. Fold change regarding the receptor expression has been calculated as the ratio between the value with IL15 and the value from a control without IL15. N/A= Not available</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
